A Phase III, Randomized, Double-Blind, Placebo Controlled, Multi- Center Study of Epratuzumab in Patients with Active Systemic Lupus Erythematosus

Trial Profile

A Phase III, Randomized, Double-Blind, Placebo Controlled, Multi- Center Study of Epratuzumab in Patients with Active Systemic Lupus Erythematosus

Discontinued
Phase of Trial: Phase III

Latest Information Update: 30 Oct 2014

At a glance

  • Drugs Epratuzumab (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Therapeutic Use
  • Acronyms ALLEVIATE-2
  • Sponsors Immunomedics; UCB Pharma Inc
  • Most Recent Events

    • 13 Jun 2012 Planned End Date changed to 1 Mar 2007, according to ClinicalTrials.gov.
    • 13 Jun 2012 Status changed from recruiting to discontinued, according to ClinicalTrials.gov.
    • 08 Jun 2012 Results presented at the 13th Annual Congress of the European League Against Rheumatism, according to an Immunomedics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top